Likes Subject
Good morning, AVXL board! It has become glaringly IH Admin [Meg Frost] 11/03/22 11:59 AM
Sources of reliable Due Diligence for new eyes: RedShoulder 07/06/22 6:37 PM
Projected Blarcamesine Revenues & Market Cap MayoMobile 07/02/22 4:12 PM
Here is a report given by Dr. Randi Hagerman. tradeherpete 04/02/22 8:03 AM
As much as I would obviously love to LBSR TO DA MOON 4 minutes ago
Most probably a P4 at most or if JWC3 12 minutes ago
Well there well be plenty good data for Investor2014 22 minutes ago
I think the bottom is in. aredrooster 38 minutes ago
Aren't we expecting a lot of news in mike_dotcom 38 minutes ago
And all that ADL noise, especially in a boi568 46 minutes ago
Maybe not today, but it's coming. This mike_dotcom 51 minutes ago
So from this presentation ADCS-ADL may not really Investor2014 53 minutes ago
Yes, I agree, boi, and that would suggest WilliamMunny 54 minutes ago
From ST-Kettil2022
Bullish
Bullish
hnbadger1 1 hour ago
What I didn't discuss was the thought that boi568 1 hour ago
While the findings are only anecdotal at this georgejjl 1 hour ago
It will be just a few weeks to JWC3 1 hour ago
Agree. sumbuysumsell 1 hour ago
I agree with you! Six to eight years BIOChecker4 1 hour ago
The 50mg dose was a clearly defined endpoint MD investor 1 hour ago
MacFarlane has been blinded as to which patients boi568 1 hour ago
Boi, please help me here and clarify, is WilliamMunny 1 hour ago
One has to be an absolute moron to itsthrillhouse 1 hour ago
Not sure what the confusion is. I meant Anshu2 1 hour ago
Once the market figures out it can be Mkc12five 1 hour ago
YOU SAID AND I QUOTE:
Bullish
Bullish
georgejjl 1 hour ago
Total Bullshit! JWC3 1 hour ago
At this rate next phase3 or any other kund 1 hour ago
REALLY? GME and AMC were not manipulated Pazzo1212 1 hour ago
Prove your false assertion... basparks79 1 hour ago
This is TOO SILLY - XenaLives 1 hour ago
So he instead, knowing what will come in growingpain 1 hour ago
LOCK UP THE CRIMINAL CABAL!!! basparks79 1 hour ago
He needed 3 years to design/think. Anshu2 1 hour ago
or perhaps its because they don't have all BarrellofHay 1 hour ago
so many here with way too much time tootalljones 1 hour ago
honestly had we billed this as phase 2 I peeved 2 hours ago
Look on the bright side: we have very frrol 2 hours ago
He started phase2b which he calls phase3/pivotal in kund 2 hours ago
It’s TOO OBVIOUS. Anshu2 2 hours ago
Why would anybody fire a CEO who is BIOChecker4 2 hours ago
THIS is the height of absurdity. XenaLives 2 hours ago
Example of a Blarcamesine super responder:
Bullish
Bullish
georgejjl 2 hours ago
Not my responsibility to prove anything. I didn't hopester 2 hours ago
Me either McMagyar 2 hours ago
Nice play, given that timing it is difficult. raja48185 2 hours ago
I am blown away by how many people BarrellofHay 2 hours ago
Reporting of the actual P value, not a
Bullish
Bullish
georgejjl 2 hours ago
FIRE MISSLING!!! jav0033 2 hours ago
Yes, but in 2014-2015, it might have been Anshu2 2 hours ago
That’s what I said.:) Anshu2 2 hours ago
I'm thrilled, I sold all of the shares XenaLives 2 hours ago
Bought moooooooore :) WolfofMia 2 hours ago
Yes, I agree. Approval is sure to JWC3 2 hours ago
Likes Subject

IH Admin [Meg Frost]
11/03/22 11:59 AM
RedShoulder
07/06/22 6:37 PM
MayoMobile
07/02/22 4:12 PM
tradeherpete
04/02/22 8:03 AM
LBSR TO DA MOON
4 minutes ago
JWC3
12 minutes ago
Investor2014
22 minutes ago
aredrooster
38 minutes ago
mike_dotcom
38 minutes ago
boi568
46 minutes ago
mike_dotcom
51 minutes ago
WilliamMunny
54 minutes ago
hnbadger1
1 hour ago
JWC3
1 hour ago
sumbuysumsell
1 hour ago
BIOChecker4
1 hour ago
WilliamMunny
1 hour ago
itsthrillhouse
1 hour ago
Mkc12five
1 hour ago
georgejjl
1 hour ago
JWC3
1 hour ago
basparks79
1 hour ago
XenaLives
1 hour ago
growingpain
1 hour ago
basparks79
1 hour ago
tootalljones
1 hour ago
Anshu2
2 hours ago
BIOChecker4
2 hours ago
XenaLives
2 hours ago
McMagyar
2 hours ago
BarrellofHay
2 hours ago
jav0033
2 hours ago
Anshu2
2 hours ago
XenaLives
2 hours ago
WolfofMia
2 hours ago

Anavex Life Sciences Corp (AVXL)

Followers
1020
Posters
Posts (Today)
206
Posts (Total)
391127
Created
12/18/07
Type
Free
Moderators RedShoulder Steady_T mrplmer 123tom kund mike_dotcom
Anavex Life Sciences Corp (AVXL)



Company website:  http://www.anavex.com/
 
 Nasdaq 
 
Company Address:
51 West 52nd Street, 7th floor
New York, NY
10019 USA
1-844-689-3939

 
CIK:  0001314052
 

Anavex®Life Sciences Corp. (the “Company”) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including drug candidates to treat Alzheimer’s disease, other central nervous system (“CNS”) diseases, pain and various types of cancer.  The Company’s lead compound ANAVEX®2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome.

Anavex®Life Sciences’ lead drug candidate, ANAVEX®2-73, recently completed successfully a Phase 2a clinical trial for Alzheimer’s disease.  ANAVEX®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors.  Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. It has also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy and others.  The Michael J. Fox Foundation for Parkinson’s Research has awarded Anavex® a research grant to develop ANAVEX®2-73 for the treatment of Parkinson’s disease to fully fund a preclinical study, which could justify moving ANAVEX®2-73 into a Parkinson’s disease clinical trial.  ANAVEX®3-71, also targeting sigma-1 and M1 muscarinic receptors, is a promising preclinical drug candidate demonstrating disease modifications against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also with beneficial effects on neuroinflammation and mitochondrial dysfunctions.

The Company is in preparation for ANAVEX®2-73 for a Phase 2/3, placebo-controlled trial in Alzheimer’s disease as well as a Phase 2, placebo-controlled trial in Rett syndrome, for which the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for ANAVEX®2-73 and a Phase 2, placebo-controlled trial in Parkinson’s disease.

Headquartered in New York, Anavex® Life Sciences is an American publicly traded corporation on Nasdaq quoted as AVXL

.
 
Management:  https://www.anavex.com/our-team/
 
Pipeline:  https://www.anavex.com/pipeline/

Patent Info: 
https://www.anavex.com/?s=patents

Clinical Trials:  https://clinicaltrials.gov/ct2/results?term=Anavex+Life+Sciences&Search=Search
 
Recent News:  https://finance.yahoo.com/q?s=avxl&ql=1

Company News Releases:  http://anavex.com/news/
 
Filings:  https://www.sec.gov/cgi-bin/browse-edgar?company=anavex&owner=exclude&action=getcompany
 
Share Structure:  See SEC filings
 
Investor Relations:  ir@anavex.com

Marketing Details:  https://www.anavex.com/investor-material/events/

 



All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
 
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
 
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp

 
New Post